>¼50%) tumors (KEYNOTE-024 (KN024) trial), and the other in combination with platinum-pemetrexed in non-squamous histology (KEYNOTE-189 (KN189)). The third trial evaluated pembrolizumab monotherapy in previously treated PD-L1positive (TPS>¼1%) advanced NSCLC (KEYNOTE-010 (KN010)). Two approaches of defining health states were considered in analyzing utility: time-to-death and progression-based health states. RESULTS: The mean utility score for the progression-free state was 0.81 (SE0.008, pembrolizumab), 0.76 (SE0.010, platinum doublet) in KN024, and 0.77 (SE0.005, pembrolizumab-platinum-pemetrexed), 0.76 (SE0.007, platinum-pemetrexed) in KN189. The utility difference between pembrolizumab monotherapy and platinum doublet in KN024 was statistically significant. The mean utility for progressive disease was 0.72(SE0.013)/0.69(SE0.013) in KN024/ KN189.The mean utility by time-to-death categories of >360 days, 180e360 days, 30e180 days, and <30 days was 0.

INTRODUCTION AND OBJECTIVES: Hilar tumors pose unique challenges during partial nephrectomy. We present the characteristics and outcomes of 263 patients with hilar tumors undergoing robot assisted partial nephrectomy (RPN) in the largest series to date.